Quantcast
Last updated on April 18, 2014 at 21:21 EDT

Kendle to Present at Upcoming Barclays Capital and Raymond James Conferences

March 9, 2009

CINCINNATI, March 9 /PRNewswire-FirstCall/ — Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization, today announced Chief Operating Officer Christopher Bergen will participate in the Barclays Capital Global Healthcare Conference on March 10 as well as the Raymond James 30th Annual Institutional Investors Conference on March 11.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080923/CLTU095LOGO )

Barclays Capital Global Healthcare Conference

The Barclays Capital Global Healthcare Conference will be held March 10-11 at the Loews Miami Beach Hotel in Miami. The Kendle presentation by Mr. Bergen is scheduled for Tuesday, March 10 at 9 a.m. Eastern Time.

The presentation will be Webcast and may be accessed at www.kendle.com in the “Investors Events & Presentations” section or at http://cc.talkpoint.com/barc002/030909a_rb/?entity=107_X2FCIEE. Slides will be available by 7 a.m. on the day of the presentation at www.kendle.com in the “Investors Events & Presentations” section.

Raymond James 30th Annual Institutional Investors Conference

The Raymond James 30th Annual Institutional Investors Conference will be held March 9-11 at the JW Marriott in Orlando, Fla. The Kendle presentation by Mr. Bergen is scheduled for Wednesday, March 11 at 7:30 a.m. Eastern Time.

The presentation will be Webcast and may be accessed at www.kendle.com in the “Investors Events & Presentations” section or at http://wsw.com/webcast/rj43/kndl/. Slides will be available by 6 a.m. on the day of the presentation at www.kendle.com in the “Investors Events & Presentations” section.

About Kendle

Kendle International Inc. (Nasdaq: KNDL) is a leading global clinical research organization providing the full range of early- to late-stage clinical development services for the world’s biopharmaceutical industry. Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery of life-enhancing drugs to market for the benefit of patients worldwide. As one of the fastest-growing global providers of Phase I-IV services, we offer experience spanning more than 100 countries, along with industry-leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers’ clinical development challenges.

Kendle was recognized by FORTUNE magazine as one of the 100 fastest- growing companies in the United States for 2008. The company also has been recognized as “Top CRO to Work With” in the CenterWatch 2007 survey of U.S. investigative sites and among the “Top CROs in Europe” in the 2008 survey of European sites.

Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 500, Cincinnati, OH 45202 or from the Company’s Web site at www.kendle.com.

SOURCE Kendle International Inc.


Source: newswire